Upadacitinib is effective in inducing clinical response and remission and is generally well tolerated in patients with ...

Guselkumab (Tremfya) showed higher 24-week fistula remission than placebo in adults with perianal fistulizing Crohn disease.

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Baseline magnetic resonance index of activity score independently predicted the longer-term need for ...

Johnson & Johnson announces positive results from phase 3 FUZION study of Tremfya in perianal fistulizing Crohn's disease: Chicago Thursday, May 7, 2026, 16:00 Hrs [IST] Johnson & ...

European researchers are using a €3m (£2.6m) grant to investigate whether MRI is a suitable tool for monitoring Crohn’s disease. MRI scans can be used as an alternative to colonoscopy when monitoring ...

One-year results: About 25% of patients achieved remission and 31% showed clinical response at 52 weeks on upadacitinib. Study design: Retrospective analysis of 59 patients across 13 French centers, ...

Doctors don’t have a clear understanding of what causes Crohn’s. But in some cases, it’s thought to involve “inappropriate” immune system activity. Basically, the immune system releases cells that ...